Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6245-6254

  Capurro, Mariana I ^a   Xiang, Yun Yan ^a   Lobe, Corrinne ^a   Filmus, Jorge ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; GLYCOSAMINOGLYCAN; GLYCOSYLPHOSPHATIDYLINOSITOL; GLYPICAN; GLYPICAN 3; MONOCLONAL ANTIBODY; POLYPEPTIDE; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG; WNT1 PROTEIN;

ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; COMPLEX FORMATION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; MEMBRANE BINDING; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION; GLYPICANS; HUMANS; IMMUNOPRECIPITATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, SCID; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION; WNT PROTEINS;

EID: 22244480967     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4244     Document Type: Article

References (73)

1. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-19.
2. Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002;99:15584-9.
3. Twombly R. Can increased treatment of hepatitis C stem the tide of liver cancer? J Natl Cancer Inst 2002;94:1050-2.
4. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46.
5. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-9.
6. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-73.
7. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997;57:5179-84.
8. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-64.
9. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:81-90.
10. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
11. Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.
12. Lander AD, Stipp CS, Ivins JK. The glypican family of heparan sulfate proteoglycans: major cell-surface proteoglycans: major cell-surface proteoglycans of the developing nervous system. Perspect Dev Neurobiol 1998;1:1-7.
13. Veugelers M, David G. The Glypicans: a family of GPI-anchored heparan sulfate proteoglycans with a potential role in the control of cell division. Trends Glycosc Glycothec 1998;10:145-52.
14. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001;108:497-501.
15. Filmus J, Song HH. Glypicans. In: Iozzo RV, editors. Proteoglycans. New York: Marcel Dekker; 2000. p. 161-76.
16. Veugelers M, De Cat B, Ceulemans H, et al. Glypican-6, a new member of the glypican family of cell surface proteoglycans. J Biol Chem 1999;274:26968-77.
17. Saunders S, Paine-Saunders S, Lander AD. Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain. Dev Biol 1997;190:78-93.
18. Baeg GH, Perrimon N. Functional binding of secreted molecules to heparan sulfate proteoglycans in Drosophila. Curr Opin Cell Biol 2000;12:575-80.
19. Jackson SM, Nakato H, Sugiura M, et al. dally, a Drosophila glypican, controls cellular responses to the TGF-β-related morphogen Dpp. Development 1997;124:4113-20.
20. Perrimon N, Bernfield M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 2000;404:725-8.
21. Topczewsky J, Sepich DS, Myers DC, et al. The Zebrafish Glypican Knypek controls cell polarity during gastrulation movements of convergent extension. Dev Cell 2001;1:251-64.
22. Ohkarawa B, Yamamoto TS, Tada M, Ueno N. Role of glypican 4 in the regulation of convergent extension movements during gastrulation in Xenopus laevis. Development 2003;130:2129-38.
23. De Cat B, Muyldermans SY, Coomans C, et al. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol 2003;163:625-35.
24. Kramer KL, Yost HJ. Heparan sulfate core proteins in cell-cell signaling. Annu Rev Genet 2003;37:461-84.
25. Baeg GH, Lin X, Khare N, Baumgartner S, Perrimon N. Heparan sulfate proteoglycans are critical for the organization of the extracellular distribution of Wingless. Development 2001;128:87-94.
26. Han C. Belenkaya TY, Wang B, Li X. Drosophila glypicans control the cell-to-cell movement of hedgehog by a dynamin-independent process. Development 2004;131:601-11.
27. Lum L, Yao S, Mozer B, et al. Identification of hedgehog pathway components by RNAi in Drosophila cultured cells. Science 2003;299:2039-45.
28. Cumberledge S, Reichsman F. Glycosaminoglycans and WNTs: just a spoonful of sugar helps the signal go down. Trends Genet 1997;13:421-3.
29. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindhal U, Emerson CP. QSulf1 remodels the 6-O sulfation states of cell surface proteoglycans to promote Wnt signaling. J Cell Biol 2003;162:341-51.
30. Feitelson MA, Sun B, Tufan NLS, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-604.
31. Kern MA, Breuhahn K, Schirmacher P. Molecular pathogenesis of human hepatocellular carcinoma. Adv Cancer Res 2002;67:112.
32. Wang XW, Hussain SP, Huo TI, et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002;181:43-7.
33. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24:245-50.
34. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24.
35. Merle P, de la Monte S, Kim M, et al. Functional consequences of Frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004;127:1110-22.
36. Duenas Gonzales A, Kaya M, Shi W, et al. OCI-5/ GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 1998;141:1407-14.
37. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001;20:7408-12.
38. Katoh M. Expression and regulation of WNT1 in human cancer: up-regulation of WNT1 by β-estradiol in MCF-7 cells. Int J Oncol 2003;22:209-12.
39. Katoh M. Differential regulation of WNT2 and WNT2B expression in human cancer. Int J Mol Med 2001;8:657-60.
40. Van den Berg DJ, Sharma AK, Bruno E, Hoffman R. Role of members of the Wnt gene family in human hematopoiesis. Blood 1998;92:3189-202.
41. Katoh M. Regulation of WNT3 and WNT3A mRNAs in human cancer cell lines NT2, MCF-7, and MKN45. Int J Oncol 2002;20:373-7.
42. Tulac S, Nayak NR, Kao LC, et al. Identification, characterization, and regulation of the canonical Wnt signaling pathway in human endometrium. J Clin Endocrinol Metab 2003;88:3860-6.
43. Saitoh T, Hirai M, Katoh M. Molecular cloning and characterization of WNT3A and WNT14 clustered in human chromosome 1q42 region. Biochem Biophys Res Commun 2001;284:1168-75.
44. Saitoh T, Katoh M. Expression and regulation of WNT5A and WNT5B in human cancer: up-regulation of WNT5A by TNFα in MKN45 cells and up-regulation of WNT5B by β-estradiol in MCF-7 cells. Int J Mol Med 2002;10:345-9.
45. Kirikoshi H, Sekihara H, Katoh M. WNT10A and WNT6, clustered in human chromosome 2q35 region with head-to-tail manner, are strongly coexpressed in SW480 cells. Biochem Biophys Res Commun 2001;283:798-805.
46. Bui TD, Lako M, Lejeune S, et al. Isolation of a full-length human WNT7A gene implicated in limb development and cell transformation, and mapping to chromosome 3p25. Gene 1997;189:25-9.
47. Kirikoshi H, Katoh M. Expression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer. Int J Oncol 2002;21:895-900.
48. Saitoh T, Mine T, Katoh M. Expression and regulation of WNT8A and WNT8B mRNAs in human tumor cell lines: up-regulation of WNT8B mRNA by β-estradiol in MCF-7 cells, and down-regulation of WNT8A and WNT8B mRNAs by retinoic acid in NT2 cells. Int J Oncol 2002;20:999-1003.
49. Kirikoshi H, Sekihara H, Katoh M. Expression of WNT14 and WNT14B mRNAs in human cancer, up-regulation of WNT14 by IFNγ and up-regulation of WNT14B by β-estradiol. Int J Oncol 2001;19:1221-5.
50. Kirikoshi H, Sekihara H, Katoh M. Molecular cloning and characterization of human WNT11. Int J Mol Med 2001;8:651-6.
51. Fear MW, Kelsell DP, Spurr NK, Barnes MR. Wnt-I6a, a novel Wnt-16 isoform, which shows differential expression in adult human tissues. Biochem Biophys Res Commun 2000;278:814-20.
52. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a b-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-7.
53. Hagihara K, Watanabe K, Chun J, Yamaguchi Y. Glypican-4 is an FGF2-binding heparan sulfate proteoglycan expressed in neural precursor cells. Dev Dyn 2000;219:353-67.
54. Filmus J. Glypicans in growth control and cancer. Glycobiology 2001;11:19-23R.
55. Muramatsu A, Iwai M, Morikawa T, et al. Influence of transfection with connexin 26 gene on malignant potential of human hepatoma cells. Carcinogenesis 2002;23:351-8.
56. Bradley RS, Brown AMC. A soluble form of Wnt-1 protein with mitogenic activity on mammary epithelial cells. Mol Cell Biol 1995;15:4616-22.
57. Clevers H. Inflating cell numbers by Wnt. Mol Cell 2002;10:1260-1.
58. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001;3:683-6.
59. Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci U S A 2001;98:15094.
60. Hussain SZ, Sneddon T, Tan X, Micsenyi A, Michalopoulos GK, Monga PS. Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res 2004;292:157-69.
61. Monga SPS, Pediaditakis P, Mule K, Stolz DB, Michalopoulos GK. Changes in Wnt/b-catenin pathway during regulated growth in rat liver degeneration. Hepatology 2001;33:1098-109.
62. Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003;423:448-52.
63. Lin H, Huber R, Schlessinger D, Morin PJ. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999;59:807-10.
64. Kim H, Xu GL, Borczuk AC, et al. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol 2003;29:694-701.
65. Murthy SS, Shen T, De Rienzo A, et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000;19:410-6.
66. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996;12:241-7.
67. Neri G, Gurrieri F, Zanni G, Lin A. Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998;79:279-83.
68. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004;6:497-506.
69. Steinfeld R, Van Den Berghe H, David G. Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. J Cell Biol 1996;133:405-16.
70. Kleef J, Ishiwata T, Kumbasar A, et al. The cell surface heparan sulfate proteoglycan glypican-1 regulates growth factor in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 1998;102:1662-73.
71. 1 arrest. Mol Cells 2003;15:356-60.
72. De La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the b-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998;95:8847-51.
73. Song HH, Shi W, Xiang Y, Filmus J. The loss of Glypican-3 induces alterations in Wnt signaling. J Biol Chem 2005;280:2116-25.